AbbVie Inc., which recently completed its acquisition of ImmunoGen Inc., has agreed to acquire Landos Biopharma Inc., a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.   Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.   &#...